229 related articles for article (PubMed ID: 30876800)
1. Preclinical Targeting of MicroRNA-214 in Cutaneous T-Cell Lymphoma.
Kohnken R; McNeil B; Wen J; McConnell K; Grinshpun L; Keiter A; Chen L; William B; Porcu P; Mishra A
J Invest Dermatol; 2019 Sep; 139(9):1966-1974.e3. PubMed ID: 30876800
[TBL] [Abstract][Full Text] [Related]
2. Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma.
Kohnken R; Wen J; Mundy-Bosse B; McConnell K; Keiter A; Grinshpun L; Hartlage A; Yano M; McNeil B; Chakravarti N; William B; Bradner JE; Caligiuri MA; Porcu P; Mishra A
Blood; 2018 Feb; 131(7):771-781. PubMed ID: 29180399
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of miR-26 promotes invasion and metastasis via targeting interleukin-22 in cutaneous T-cell lymphoma.
Matsuda Y; Ikeda S; Abe F; Takahashi Y; Kitadate A; Takahashi N; Wakui H; Tagawa H
Cancer Sci; 2022 Apr; 113(4):1208-1219. PubMed ID: 35133054
[TBL] [Abstract][Full Text] [Related]
5. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
Wang Y; Gu X; Li W; Zhang Q; Zhang C
J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.
Kitadate A; Ikeda S; Teshima K; Ito M; Toyota I; Hasunuma N; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
Oncogene; 2016 Jul; 35(28):3692-704. PubMed ID: 26640145
[TBL] [Abstract][Full Text] [Related]
7. Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma.
Mishra A; La Perle K; Kwiatkowski S; Sullivan LA; Sams GH; Johns J; Curphey DP; Wen J; McConnell K; Qi J; Wong H; Russo G; Zhang J; Marcucci G; Bradner JE; Porcu P; Caligiuri MA
Cancer Discov; 2016 Sep; 6(9):986-1005. PubMed ID: 27422033
[TBL] [Abstract][Full Text] [Related]
8. Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-Cell Lymphomas.
Dusílková N; Bašová P; Polívka J; Kodet O; Kulvait V; Pešta M; Trněný M; Stopka T
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29036928
[TBL] [Abstract][Full Text] [Related]
9. miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma.
Manfè V; Biskup E; Rosbjerg A; Kamstrup M; Skov AG; Lerche CM; Lauenborg BT; Odum N; Gniadecki R
PLoS One; 2012; 7(1):e29541. PubMed ID: 22235305
[TBL] [Abstract][Full Text] [Related]
10. STAT5 induces miR-21 expression in cutaneous T cell lymphoma.
Lindahl LM; Fredholm S; Joseph C; Nielsen BS; Jønson L; Willerslev-Olsen A; Gluud M; Blümel E; Petersen DL; Sibbesen N; Hu T; Nastasi C; Krejsgaard T; Jæhger D; Persson JL; Mongan N; Wasik MA; Litvinov IV; Sasseville D; Koralov SB; Bonefeld CM; Geisler C; Woetmann A; Ralfkiaer E; Iversen L; Odum N
Oncotarget; 2016 Jul; 7(29):45730-45744. PubMed ID: 27329723
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-150 inhibits tumor invasion and metastasis by targeting the chemokine receptor CCR6, in advanced cutaneous T-cell lymphoma.
Ito M; Teshima K; Ikeda S; Kitadate A; Watanabe A; Nara M; Yamashita J; Ohshima K; Sawada K; Tagawa H
Blood; 2014 Mar; 123(10):1499-511. PubMed ID: 24385540
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL).
Ralfkiaer U; Hagedorn PH; Bangsgaard N; Løvendorf MB; Ahler CB; Svensson L; Kopp KL; Vennegaard MT; Lauenborg B; Zibert JR; Krejsgaard T; Bonefeld CM; Søkilde R; Gjerdrum LM; Labuda T; Mathiesen AM; Grønbæk K; Wasik MA; Sokolowska-Wojdylo M; Queille-Roussel C; Gniadecki R; Ralfkiaer E; Geisler C; Litman T; Woetmann A; Glue C; Røpke MA; Skov L; Odum N
Blood; 2011 Nov; 118(22):5891-900. PubMed ID: 21865341
[TBL] [Abstract][Full Text] [Related]
13. Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.
Litvinov IV; Cordeiro B; Fredholm S; Ødum N; Zargham H; Huang Y; Zhou Y; Pehr K; Kupper TS; Woetmann A; Sasseville D
Cell Cycle; 2014; 13(18):2975-82. PubMed ID: 25486484
[TBL] [Abstract][Full Text] [Related]
14. miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma.
McGirt LY; Adams CM; Baerenwald DA; Zwerner JP; Zic JA; Eischen CM
J Invest Dermatol; 2014 Apr; 134(4):1101-1107. PubMed ID: 24304814
[TBL] [Abstract][Full Text] [Related]
15. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
Sibbesen NA; Kopp KL; Litvinov IV; Jønson L; Willerslev-Olsen A; Fredholm S; Petersen DL; Nastasi C; Krejsgaard T; Lindahl LM; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Iversen L; Bonefeld CM; Geisler C; Woetmann A; Odum N
Oncotarget; 2015 Aug; 6(24):20555-69. PubMed ID: 26244872
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma.
Ralfkiaer U; Lindahl LM; Litman T; Gjerdrum LM; Ahler CB; Gniadecki R; Marstrand T; Fredholm S; Iversen L; Wasik MA; Bonefeld CM; Geisler C; Krejsgaard T; Glue C; Røpke MA; Woetmann A; Skov L; Grønbæk K; Odum N
Anticancer Res; 2014 Dec; 34(12):7207-17. PubMed ID: 25503151
[TBL] [Abstract][Full Text] [Related]
17. MicroRNAs in Cutaneous T-Cell Lymphoma: The Future of Therapy.
Kohnken R; Mishra A
J Invest Dermatol; 2019 Mar; 139(3):528-534. PubMed ID: 30686578
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic Silencing of Tumor Suppressor miR-124 Directly Supports STAT3 Activation in Cutaneous T-Cell Lymphoma.
García-Colmenero L; González J; Sandoval J; Guillén Y; Diaz-Lagares A; Andrades E; Iglesias A; Nonell L; Pujol RM; Bigas A; Espinosa L; Gallardo F
Cells; 2020 Dec; 9(12):. PubMed ID: 33333886
[TBL] [Abstract][Full Text] [Related]
19. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
[TBL] [Abstract][Full Text] [Related]
20. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma.
Miyagaki T; Sugaya M; Suga H; Kamata M; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Clin Cancer Res; 2011 Dec; 17(24):7529-38. PubMed ID: 22048239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
